A phase II evaluation of fazarabine in high-grade gliomas: a Southwest Oncology Group study

Cancer Chemother Pharmacol. 1994;34(2):179-80. doi: 10.1007/BF00685938.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Multicenter Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Astrocytoma / drug therapy
  • Azacitidine / adverse effects
  • Azacitidine / therapeutic use*
  • Brain Neoplasms / drug therapy
  • Female
  • Glioblastoma / drug therapy
  • Glioma / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Southwestern United States
  • Treatment Failure

Substances

  • Antineoplastic Agents
  • fazarabine
  • Azacitidine